A Review on Commercial Oligonucleotide Drug Products
Journal of Pharmaceutical Sciences · 2024-07 · 113 (7) · 1749-1768
DOI: 10.1016/j.xphs.2024.04.021 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Pharmaceutical Sciences, 2024-07. Verfasst von Bhavani Prasad Vinjamuri und 2 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Operations & Technology, Biogen, 225 Binney Street, Cambridge, MA 02142, United States. Electronic address: bhavaniprasad.vinjamuri@bi…. Hauptthemen laut MEDLINE: Oligonucleotides. Die Arbeit wurde bisher 95-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Biogen.
Abstract (Originalsprache)
Oligonucleotide drug products commercially approved in the US and the EU are reviewed. A total of 20 products that includes 1 aptamer, 12 antisense oligonucleotides (ASOs), 6 small interfering ribonucleic acids (siRNAs), and 1 mixture of single-stranded and double-stranded polydeoxyribonucleotides have been identified. A typical oligonucleotide formulation is composed of an oligonucleotide with buffering agent(s), pH adjusting agents, and a tonicity adjusting agent. All the products are presented as 2.1 - 200 mg/mL solutions at pH between 6 and 8.7. Majority of the products are approved for intravenous (IV) and subcutaneous (SC) routes, with two for intravitreal (IVT), two for intrathecal (IT), and one for intramuscular (IM) routes. The primary packaging includes vials and prefilled syringes (PFS). Products approved for IV and IT administration routes and requiring >1.5 mL dose volumes are supplied in vials, while those approved for SC, IM, and IVT and requiring ≤1.5 mL dose volume are supplied in PFS. Based on the compiled dataset, we propose a generalized starting point for an oligonucleotide formulation during early phase development for IV, SC, and IT administration routes. Overall, we believe this harmonized evaluation and understanding of various oligonucleotide drug product attributes will help derive platform generalizations and allows for accelerated early phase development for first-in-human studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Operations & Technology, Biogen, 225 Binney Street, Cambridge, MA 02142, United States. Electronic address: bhavaniprasad.vinjamuri@biogen.com.
- Pharmaceutical Operations & Technology, Biogen, 225 Binney Street, Cambridge, MA 02142, United States.
- Pharmaceutical Operations & Technology, Biogen, 225 Binney Street, Cambridge, MA 02142, United States. Electronic address: paul.peng@biogen.com.
Förderung
- Biogen
Zitieren
APA
Vinjamuri, B. P., Pan, J., & Peng, P. (2024). A Review on Commercial Oligonucleotide Drug Products. Journal of Pharmaceutical Sciences, 113(7), 1749-1768. https://doi.org/10.1016/j.xphs.2024.04.021
Vancouver
Vinjamuri BP, Pan J, Peng P. A Review on Commercial Oligonucleotide Drug Products. Journal of Pharmaceutical Sciences. 2024;113(7):1749-1768. doi:10.1016/j.xphs.2024.04.021
BibTeX
@article{Vinjamuri2024,
author = {Vinjamuri, Bhavani Prasad and Pan, Jiayi and Peng, Paul},
title = {A Review on Commercial Oligonucleotide Drug Products},
journal = {Journal of Pharmaceutical Sciences},
year = {2024},
volume = {113},
number = {7},
pages = {1749--1768},
doi = {10.1016/j.xphs.2024.04.021}
}
EUVIMED